Elevance Health Inc. reported first‑quarter 2026 operating revenue of $49.5 billion, a 1.5% year‑over‑year increase, and net income of $1.76 billion, a 19.3% decline from the $2.18 billion earned in Q1 2025. Diluted earnings per share were $8.00, down from $9.61 in the prior year, reflecting higher medical costs and a 40‑basis‑point rise in the benefit expense ratio to 86.8%.
The Health Benefits segment grew 2.6% in revenue, driven by higher premium yields, and its operating margin fell to 5.1% from 5.4% in Q1 2025. The Carelon Services and CarelonRx units combined grew 7.9% in revenue, with total Carelon operating revenue reaching $18.0 billion. These results illustrate the company’s continued focus on high‑margin commercial and Medicare Advantage plans while managing cost pressures in Medicaid and other legacy lines.
Elevance’s benefit expense ratio climbed to 86.8%, a 40‑basis‑point increase largely attributable to elevated Medicaid medical cost trends. The company also recorded a $935 million accrual for potential exposure related to a CMS notice of intended sanctions, a one‑time GAAP charge that does not affect its operating outlook. In addition, the company earned approximately $1 per share from non‑recurring investment income, which helped lift adjusted earnings and support the guidance raise.
Operating cash flow for the quarter was $4.3 billion, providing the liquidity needed to fund its capital allocation program and maintain financial flexibility.
Management raised its full‑year adjusted EPS guidance to at least $26.75 from $26.50, citing improved claims experience, cost‑control initiatives, and a stronger mix of higher‑margin commercial and Medicare Advantage plans. The guidance increase signals confidence in the company’s margin reset strategy and its ability to navigate the 2026 margin trough while positioning for a 2027 profitability recovery.
"Our first quarter results exceeded expectations, reflecting underlying business strength and improving claims experience. We are raising our full‑year adjusted EPS guidance, supported by greater visibility into the balance of the year," said President and CEO Gail K. Boudreaux. "The $935 million accrual for potential exposure related to the CMS notice is our current best estimate and does not affect our operating outlook," she added.
Investors reacted positively to the earnings report, with the market citing the earnings beat, revenue performance, and guidance raise as key drivers. The company’s strong operating cash flow and resilience amid the one‑time GAAP charge reinforced confidence in its ongoing execution strategy.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.